Cardiff Regional Experimental Arthritis Treatment and Evaluation Centre (CREATE)
The Cardiff Regional Experimental Arthritis Treatment and Evaluation Centre works alongside volunteer patients from Cardiff and the Vale University Health Board, to develop and test drugs to treat patients with Rheumatoid and Psoriatic arthritis.
The CREATE Centre is part of the Rheumatology section within the School of Medicine.
We work alongside volunteer patients from Cardiff and the Vale University Health Board, to develop and test drugs to treat patients with Rheumatoid and Psoriatic arthritis. We are jointly funded by Arthritis Research UK, Health and Care Research Wales and Cardiff University.
Rheumatoid and Psoriatic Arthritis are chronic inflammatory joint conditions that result in pain, disability, joint damage and reduced quality of life. Achieving and sustaining remission has been shown to be important in arresting joint damage and improve prognosis. However, the percentage of patients who attain remission in clinical practice is estimated to be less than 30 per cent.
- To improve the outcome of patients with rheumatoid and psoriatic arthritis by developing new treatments and diagnostic tests that will lead to more patients achieving disease remission.
If you would like to find out more about the centre or are interested in engaging with us please contact us by email.
We have established collaboration with other researchers in the area of infection and immunity to identify novel targets and develop new treatment.
Testing these novel treatments in patients with Rheumatoid and Psoriatic Arthritis will be facilitated by the South East Wales Trials Unit and the Clinical Research Facility at University Hospital of Wales.
Meet the team
- Atwan, A. et al., 2016. Oral fumaric acid esters for psoriasis: abridged Cochrane systematic review including GRADE assessments. British Journal of Dermatology 175 (5), pp.873-881. (10.1111/bjd.14676)
- Olsen, J. R. et al., 2016. Quality of life impact of childhood skin conditions measured using the Children's Dermatology Life Quality Index (CDLQI): a meta-analysis. British Journal of Dermatology 174 (4), pp.853-861. (10.1111/bjd.14361)
- Bloom, A. C. et al., 2016. Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice. Bone 84 , pp.253-261. (10.1016/j.bone.2015.12.014)
- Marchettini, P. et al., 2016. Are there different predictors of analgesic response between antidepressants and anticonvulsants in painful diabetic neuropathy?. European Journal of Pain 20 (3), pp.472-482. (10.1002/ejp.763)
- Jones, G. W. and Jones, S. A. 2016. Ectopic lymphoid follicles: inducible centres for generating antigen-specific immune responses within tissues. Immunology 147 (2), pp.141-151. (10.1111/imm.12554)
- Phillips, K. et al., 2015. Harmonizing pain outcome measures: results of the Pre-OMERACT meeting on partnerships for consensus on patient-important pain outcome domains between the Cochrane Musculoskeletal Group and OMERACT. Journal of Rheumatology 42 (10), pp.1943-1946. 194386. (10.3899/jrheum.141386)
- Taylor, A. M. et al. 2015. Is chronic pain a disease in its own right? Discussions from a Pre-OMERACT 2014 Workshop on chronic pain. Journal of Rheumatology 42 (10), pp.1947-1953. (10.3899/jrheum.141328)
- Atwan, A. et al., 2015. Oral fumaric acid esters for psoriasis. Cochrane Database of Systematic Reviews (8) CD010497. (10.1002/14651858.CD010497.pub2)
- Hewlett, S. et al., 2015. Protocol for a randomised controlled trial for Reducing Arthritis Fatigue by clinical Teams (RAFT) using cognitive-behavioural approaches. BMJ Open 5 (8) e009061. (10.1136/bmjopen-2015-009061)
- Ibrahim, F. et al., 2015. Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rhuematology 54 (6), pp.1050-1055. (10.1093/rheumatology/keu442)
- Choy, E. H. S. 2015. The role of sleep in pain and fibromyalgia. Nature Reviews Rheumatology 11 (9), pp.513-520. (10.1038/nrrheum.2015.56)
- Collins, F. L. et al., 2015. Death Receptor 3 (TNFRSF25) Increases mineral apposition by osteoblasts and region specific new bone formation in the axial skeleton of male DBA/1 mice. Journal of Immunology Research 2015 , pp.-. 901679. (10.1155/2015/901679)
- Giles, J. et al. 2015. Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis. The Journal of Immunology 194 (7), pp.3029-3034. (10.4049/jimmunol.1402956)
- Bonnet, C. S. et al. 2014. AMPA/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis. Annals of the Rheumatic Diseases 74 , pp.242-251. (10.1136/annrheumdis-2013-203670)
- Jones, S. A. et al. 2014. Interleukin-6 in renal disease and therapy. Nephrology Dialysis Transplantation 30 (4), pp.564-574. (10.1093/ndt/gfu233)